Authors
Dina Visca, Letizia Mori, Vicky Tsipouri, Sharon Fleming, Ashi Firouzi, Matteo Bonini, Matthew J Pavitt, Veronica Alfieri, Sara Canu, Martina Bonifazi, Cristina Boccabella, Angelo De Lauretis, Carmel JW Stock, Peter Saunders, Andrew Montgomery, Charlotte Hogben, Anna Stockford, Margaux Pittet, Jo Brown, Felix Chua, Peter M George, Philip L Molyneaux, Georgios A Margaritopoulos, Maria Kokosi, Vasileios Kouranos, Anne Marie Russell, Surinder S Birring, Alfredo Chetta, Toby M Maher, Paul Cullinan, Nicholas S Hopkinson, Winston Banya, Jennifer A Whitty, Huzaifa Adamali, Lisa G Spencer, Morag Farquhar, Piersante Sestini, Athol U Wells, Elisabetta A Renzoni
Publication date
2018/10/1
Journal
The Lancet Respiratory Medicine
Volume
6
Issue
10
Pages
759-770
Publisher
Elsevier
Description
Background
In fibrotic interstitial lung diseases, exertional breathlessness is strongly linked to health-related quality of life (HRQOL). Breathlessness is often associated with oxygen desaturation, but few data about the use of ambulatory oxygen in patients with fibrotic interstitial lung disease are available. We aimed to assess the effects of ambulatory oxygen on HRQOL in patients with interstitial lung disease with isolated exertional hypoxia.
Methods
AmbOx was a prospective, open-label, mixed-method, crossover randomised controlled clinical trial done at three centres for interstitial lung disease in the UK. Eligible patients were aged 18 years or older, had fibrotic interstitial lung disease, were not hypoxic at rest but had a fall in transcutaneous arterial oxygen saturation to 88% or less on a screening visit 6-min walk test (6MWT), and had self-reported stable respiratory symptoms in the previous 2 weeks. Participants …
Scholar articles
D Visca, L Mori, V Tsipouri, S Fleming, A Firouzi… - The Lancet Respiratory Medicine, 2018